43 results about "Quercetin Glycoside" patented technology

An extract from Sunset Abelmoschus, containing 50-75wt% of total flavone counted by hyperin, wherein, the contents of hyperin, isoquercitrin and quercetin-3'-glucoside are 10.0-15.0wt%, 7.0-12.0wt% and 8.0-12.0wt% respectively, and a total flavone finger-print is provided. The extract is obtained by the following steps: a concentrated solution of a Sunset Abelmoschus ethanol extract undergoes chromatography through an HPD400 or HPD700 macroporous absorbent resin column to derive a crude extract or is extracted by normal butanol to derive the crude extract; a refined extract is obtained by refluxing extraction with ethyl acetate-ethanol azeotropic mixture or ethyl acetate-methanol mixture; the refined extract goes through pressure reducing exsolution and drying. Corresponding contents and a method for detecting finger-print are also provided. The extract preparation is a dripping pill, tablet, capsule or soft capsule obtained through processing with the extract as an active ingredient and pharmaceutical excipients. The extract can be used for preparing a medicine preparation for treating cardiac anencephalohemia diseases.

The invention discloses a wikstroemia indica (L.) C.A.Mey extract as well as a preparation method and application thereof. The wikstroemia indica (L.) C.A.Mey extract has the effective compositions of: naringenin, 5, 6, 7- trihydroxy-4'-methoxyflavanone, p-hydroxybenzoic acid, benzoic acid, quercetin glycoside,genkwano1 B, daphnoretin, Lirioresinol, Sikokianin and the like. The invention simultaneously provides application of the wikstroemia indica (L.) C.A.Mey extract, in particular the favorable application in preparing anti-cancer or anti-inflammation analgesia drug. A cytotoxicity experiment shows that the wikstroemia indica (L.) C.A.Mey extract disclosed by the invention has cytotoxicity functions on breast cancer of human, breast cancer drugresistant cell strain, mouse breast adenocarcinoma, which are in linear relation.

The invention relates to the field of extraction of natural compounds, in particular to a method for separating flavonoid components in annona squamosa leaves. An ethanol extract of the annona squamosa leaves is subjected to dealcoholization, petroleum ether degreasing and n-butyl alcohol extraction to obtain a crude flavonoid extract, and the crude flavonoid extract is distributed by a two-phasesolvent to obtain a total flavonoid sample. By means of high-speed countercurrent chromatography, a secondary flavonoid extract is separated and purified to obtain quercetin-3-O-beta-D-glucoside, kaempferol-3-O-robinobioside, kaempferol-3-O-rutinoside, quercetin-3-O-robinobioside and rutin, and the purity is 95% or above. The invention further provides a method for separating the flavonoid components through linear elution. High-purity monomer can be obtained, and the method has good popularization significance.

The present invention is schefflera venulosa extract and its preparation process and use in preparing medicine. The schefflera venulosa extract contains mainly caffeoyl acids 5-40 wt%, quercetin glycoside 15-55 wt% and oleanolic acid glycoside 15-45 wt%. The schefflera venulosa extract may be prepared into orally taken preparation or injection alone or together with pharmaceutically acceptable supplementary material, and the medicine preparation may be used in promoting blood circulation to disperse blood clots, improving microcirculation, and preventing and treating acute myocardial ischemia, coronary heart disease, angina pectoris and other cardiac and cerebral vascular diseases.

The present invention provides an α-glycosyl isoquercitrin-containing novel composition which has a high in vivo absorbability, and hence exhibits a significant in vivo antioxidative activity. The present invention further provides preparation methods for such a composition. The composition contains a mixture of quercetin glycosides represented by the following formula:

wherein Glc represents a glucose residue, and n is 0 or a positive integer of 1 or more,

includes at least a quercetin glycoside wherein n is 3, and satisfies the following requirement (a):

(a) the total proportion of quercetin glycosides in which n is 3, and in which other n values may be 1 or 2, or 1 and 2, is 50 mol % or more, and the total proportion of quercetin glycosides wherein n is 4 or more is 15 mol % or less, in the composition. The composition can be prepared by treating an enzymatically modified isoquercitrin with β-amylase.

The invention discloses a method for biosynthesis of quercetin glycoside, which connects the gene of glycosyltransferase UGT73G1 or mutant thereof with sucrose synthase gene to obtain a recombinant plasmid, and constructs a recombinant bacterium containing a double enzyme system; The recombinant strain was inoculated in LB liquid medium, cultured at 25-40 DEG C until OD600 reached 2-3, adding inducer lactose to induce for 12 to 20 hour, centrifuging that fermentation broth to collect bacterial cells, crushing the bacterial cell, and centrifuging to collect supernatant to obtain crude enzyme solution; dissolving quercetin or isoquercetin in DMSO, add crude enzyme solution, sucrose, reaction 8-30 h, adding methanol to stop that reaction, and centrifuging to obtain the supernatant quercetin-3, 4'-Diglucoside; diglucoside. The amino acid sequence of the glycosyltransferase mutant is an amino acid sequence in which the amino acid sequence shown in SEQID NO: 1 is mutated, and the mutated amino acid site is selected from one or more of S151, T168, K274, T293, G361, S365, V371 and F381. The mutant is simple in preparation and high in yield, and realizes the function of quercetin The yieldof 3, 4 '-diglucoside was increased.

An object of the present invention is to provide a new muscle atrophy inhibitor comprising a component that is safely ingestible for a long time.

It was found that glycosides of quercetin, a polyphenol present in plants, etc., have inhibitory activity on the expression of myostatin involved in muscle atrophy. This invention provides a new muscle atrophy inhibitor comprising a quercetin glycoside which is excellent in absorbability into the body and high in safety.

A quercetin glycoside and a fructooligosaccharide in a ratio (by weight) of 1 to at least 0.1 are incorporated to produce a quercetin glycoside-containing oral composition and to mitigate the bitterness of the quercetin glycoside contained therein.

A method is provided for preventing or treating bone or musculoskeletal metabolism disorders or kidney malfunction in humans. It comprises providing to a subject in need of that a calcium containing or calcium enriched diet combined with the administration of an efficient amount of a plant extract of Solatium glaucophyllum comprising from about 0.8 to about 2.2 weight % of a mixture of 1,25-dihydroxyvitamin D3 glycosides and quercetin glycosides present in a ratio of about 1:100 to 1:200 parts by weight. There are also provided food or dietary composition and food supplement designed for preventing or treating bone or musculoskeletal metabolism disorders or kidney malfunction in humans which comprises an efficient amount of the said plant extract of Solanum glaucophyllum and a source of calcium.

The invention discloses a method for extracting and separating flavonoid components in lindera aggregata leaves. The method comprises the following steps: mixing the lindera aggregata leaves with an adsorbent, performing eluting by adopting a matrix solid-phase dispersion extraction method, and performing concentrating to obtain a lindera aggregata leaf extract; performing primary separation and secondary separation treatment on the lindera aggregata leaf extract by adopting a high-speed counter-current chromatography, so as to realize separation of quercetin-3-O-beta-D-arabinofuranoside, a mixture of quercetin-3-O-beta-D-glucoside and quercetin-5-O-beta-D-glucoside, quercetin-3-O-rhamnopyranoside and kaempferol-7-O-alpha-L-rhamnopyranoside, wherein a second solvent system adopted in the secondary separation treatment comprises ethyl acetate, n-butyl alcohol, a resolving agent and water, and the resolving agent comprises cyclodextrin. According to the method provided by the invention, the flavonoid components purified and separated from the lindera aggregata leaves have the advantages of short separation period, high separation efficiency and few impurities.

The purpose of the present invention is to provide a means of enhancing the bodily absorption of sesamin-class compounds. By using sesamin-class compounds and quercetin glycosides in combination, the bodily absorption of the sesamin-class compounds can be enhanced.

The invention relates to an abelmoschus manihot flower flavonoid effective part and a preparation method and an application thereof, and belongs to the field of medicine, the abelmoschus manihot flower flavonoid effective part comprises the following flavonoid components: quercetin, and quercetin-3'-O-glucoside, myricetin, gossypoin-8-O-beta-D-glucuronide, isoquercitrin, rutin and hyperoside, the mass ratio of the above components is 1:13-33:1-7:14-38:12-32:1-5:18-42,and the abelmoschus manihot flower flavonoid effective part has good effects of preventing or treating skin aging, repairing and resisting aging.

The present invention aims to provide a container-bottled drink for matching with quercetin glycoside, which can ensure high stability of the quercetin glycoside after long-term storage. Particularly, pH value of the drink is 5.6-6.4, and the drink contains ascorbic acid as a drink component, wherein the amount of the ascorbic acid is above an effective amount for preventing oxidation and is lower than 400ppm. According to the container-bottled drink for matching with the quercetin glycoside, the pH value is 5.6-6.4. The container-bottled drink contains the ascorbic acid as the drink component, and the amount of the ascorbic acid is above an effective amount for preventing oxidation and is lower than 400ppm.

The invention discloses a method for purifying quercetin glucoside in semen lepidii. The method is characterized by comprising the following steps of (1) carrying out primary water extraction on quercetin-3-O-beta-D-glucose-7-O-beta-D-gentiobioside in the semen lepidii; (2) performing alcohol precipitation and impurity removal on the semen lepidii water extract; (3) eluting and separating by using LX-68G type macroporous resin; (4) eluting and purifying with a CM-agarose gel FF column; and (5) carrying out preparative liquid phase purification, so as to obtain a quercetin-3-O-beta-D-glucose-7-O-beta-D-gentiobioside monomeric compound. Experimental results show that the CM-agarose gel FF has a good purification effect on quercetin-3-O-beta-D-glucose-7-O-beta-D-gentiobioside, the purity of a sample subjected to preparative liquid phase separation and purification can reach 99.0% or above, the technical requirement that the purity of the sample is larger than 98.5% of a national traditional Chinese medicine reference substance is met, and the obtained product can be used as the traditional Chinese medicine reference substance.